IsoPlexis is empowering cell therapy development across the discovery-optimize-predict continuum
From discovery to the clinic, researchers are developing a far more complicated cell based product to address a variety of cancers therapeutically. To characterizate these solutions, more detail is needed to address challenges related to potency, durability and toxicities that correlate to what is happening in vivo within the cell therapy.
IsoPlexis has worked with leaders to develop data correlating with response:
Cell Engineering & Therapy
Join us to learn more about how we are accelerating cell therapy programs across the discover-optimize-predict continuum with our unique cellular analysis metrics.
IsoPlexis' systems are revealing cellular potency differences resulting from subtle CRISPR gene edits to NK cells
Our products help identify methodologies for increasing potency in cell therapy bioprocessing
Our systems are identifying pre-infusion cell therapy product metrics (PSITM) that correlate with in vivo outcome
on our datasets >[/ce_button]
Notch activation rescues exhaustion in CISH-deleted natural killer cells to promote in vivo persistence and enhance anti-tumor activity. Zhu H, Blum RH, Wu Z, Bahena A, Hoel HJ, Ask EH, Guan KL, Malmberg KJ, Kaufman DS. Presented at ASH Annual Meeting 2018.
Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes. Kotani H, Li Gongbo, Yao Jiqiang, Mesa TE, Chen J, Boucher JC, Yoder SJ, Zhou J, Davila ML. Presented at ASH Annual Meeting 2018.
Single-Cell Multiplexed Cytokine Profiling of CD19 CAR-T Cells Reveals a Diverse Landscape of Polyfunctional Antigen-Specific Response. Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, Kodrasi O, Quigley M, Heath JR, Fan R, Mackay S, Dudley M, Kassim S, and Zhou J. Journal for ImmunoTherapy of Cancer, 5:85 (2017).
Single-Cell Proteomic Assessment of CD19 CAR-T Cells Reveals a Complex Landscape of Polyfunctional Antigen-Specific Response. Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, McConnell T, Kodrasi O, Quigley M, Heath JR, Fan R, Mackay S, Dudley M, Kassim S, and Zhou J. Presented at FOCiS Annual Meeting 2017.
Abbreviated T-cell activation on the automatic CliniMACS Prodigy device enhances bispecific CD19/22 Chimeric Antigen Receptor T-cell viability and fold expansion, reducing total culture duration. Srivastava SK, Panch SR, Jin J, Shalabi H, Shah NN, Flynn B, Zhou J, Mackay S, Highfill SL, Stroncek DF. Presented at ASH Annual Meeting 2018.
Single-Cell Multiplex Proteomics Reveals Synergistic Impact of Antigen and Rimiducid-Dependent Stimulatory Signals on Promoting Polyfunctional GoCAR-T cells Targeting Prostate Stem Cell Antigen (PSCA). Mackay S, Flynn B, Morse K, Ng C, Paczkowski P, Mahendravada A, Shinners N, Spencer D, Foster A, and Zhou J. Blood 130 (Suppl. 1) 2281 (2017).
Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL. Rossi J, Paczkowski P, Shen Y, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath JR, Rosenberg SA, Kochenderfer JN, Zhou J, and Bot A. Blood 2018.